 |
Medytox.(photo=medytox) |
[Alpha Biz= Reporter Kim Jisun] Medytox, which is engaged in a legal battle with the Ministry of Food and Drug Safety over the cancellation of its botulinum toxin product licenses, has achieved a partial victory in the second round of administrative litigation.
On the 13th, the Daejeon High Court's Administrative Division 1 ruled partially in
favor of Medytox in the lawsuit filed against the Ministry of Food and Drug Safety and others, seeking to cancel the revocation of the pharmaceutical product licenses and the suspension of manufacturing and sales. The court decided to cancel the orders for the revocation of the product licenses and the suspension of manufacturing. However, it upheld the one-month suspension of sales operations as lawful.
Previously, Medytox had indirectly exported botulinum toxin intended for export through a sales agency to China and other countries. The Ministry of Food and Drug Safety ordered the recall and destruction of the products, stating that they were sold without national lot release approval. National lot release approval is a system in which the state verifies the quality of biological products requiring health and hygiene precautions before they are distributed in the market.
Medytox argued that the products did not require national lot release approval and filed a lawsuit to cancel the administrative measures taken by the Ministry. In November last year, the Daejeon District Court’s Administrative Division 3 ruled in favor of Medytox's claim. However, the Ministry of Food and Drug Safety appealed the decision, leading to the second round of litigation.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
